Identification of a potent V3 glycan site broadly neutralizing antibody targeting an N332 glycan-independent epitope

Journal:

Nature Immunology

Published:

2026-02-03

DOI:

10.1038/s41590-025-02385-3

Affiliations:

24

Authors:

37

Go to article

Institutions	Authors	Share
University Hospital of Cologne, Germany	10.916667 10.916667	0.30
The University of Alabama at Birmingham (UAB), United States of America (USA)	5.000000	0.14
California Institute of Technology (Caltech), United States of America (USA)	4.000000	0.11
National Institute for Medical Research (NIMR), Tanzania	3.000000	0.08
Basic Sciences Division, FHCRC, United States of America (USA)	2.000000	0.05
Amsterdam UMC, Netherlands	2.000000	0.05
Vir Biotechnology, United States of America (USA)	2.000000	0.05
Vir Biotechnology Switzerland, Switzerland	2.000000	0.05
University Hospital of Munich (KUM), LMU, Germany	1.250000	0.03
DZIF Partner Site Munich, Germany	1.250000	0.03
DZIF Partner Site Bonn-Cologne, Germany	1.083333	0.03
Beth Israel Deaconess Medical Center (BIDMC), United States of America (USA)	1.000000	0.03
Vanderbilt University Medical Center (VUMC), United States of America (USA)	0.600000	0.02
Vanderbilt University (VU), United States of America (USA)	0.400000	0.01
Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Germany	0.250000	0.01
Helmholtz Zentrum München - German Research Center for Environmental Health (HMGU), Germany	0.250000	0.01
Howard Hughes Medical Institute (HHMI), United States of America (USA)	0.000000	0.00

Interested in Clinical Sciences?